BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 15567460)

  • 1. Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting.
    Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Barrera-Ramirez C; Sabaté M; Hernández R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Costa MA; Bass TA; Macaya C
    Thromb Res; 2005; 115(1-2):101-8. PubMed ID: 15567460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is a 300 mg clopidogrel loading dose sufficient to inhibit platelet function early after coronary stenting? A platelet function profile study.
    Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Sabaté M; Hernández-Antolín R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Macaya C
    J Invasive Cardiol; 2004 Jun; 16(6):325-9. PubMed ID: 15156004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability.
    Angiolillo DJ; Fernández-Ortiz A; Bernardo E; Ramírez C; Sabaté M; Bañuelos C; Hernández-Antolín R; Escaned J; Moreno R; Alfonso F; Macaya C
    Eur Heart J; 2004 Nov; 25(21):1903-10. PubMed ID: 15522469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial.
    Gurbel PA; Cummings CC; Bell CR; Alford AB; Meister AF; Serebruany VL;
    Am Heart J; 2003 Feb; 145(2):239-47. PubMed ID: 12595840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance.
    Lev EI; Patel RT; Maresh KJ; Guthikonda S; Granada J; DeLao T; Bray PF; Kleiman NS
    J Am Coll Cardiol; 2006 Jan; 47(1):27-33. PubMed ID: 16386660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Failure of clopidogrel to reduce platelet reactivity and activation following standard dosing in elective stenting: implications for thrombotic events and restenosis.
    Gurbel PA; Samara WM; Bliden KP
    Platelets; 2004 Mar; 15(2):95-9. PubMed ID: 15154601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted?
    Angiolillo DJ; Fernández-Ortiz A; Bernardo E; Barrera Ramírez C; Sabaté M; Fernandez C; Hernández-Antolín R; Escaned J; Alfonso F; Macaya C
    J Invasive Cardiol; 2004 Apr; 16(4):169-74. PubMed ID: 15152138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease.
    Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Cavallari U; Trabetti E; Sabaté M; Jimenez-Quevedo P; Hernández R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Costa MA; Bass TA; Pignatti PF; Macaya C
    Thromb Res; 2005; 116(6):491-7. PubMed ID: 16181985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?
    Bliden KP; DiChiara J; Tantry US; Bassi AK; Chaganti SK; Gurbel PA
    J Am Coll Cardiol; 2007 Feb; 49(6):657-66. PubMed ID: 17291930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial.
    Serebruany VL; Malinin AI; Jerome SD; Lowry DR; Morgan AW; Sane DC; Tanguay JF; Steinhubl SR; O'connor CM
    Am Heart J; 2003 Oct; 146(4):713-20. PubMed ID: 14564328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
    Sibbing D; Braun S; Morath T; Mehilli J; Vogt W; Schömig A; Kastrati A; von Beckerath N
    J Am Coll Cardiol; 2009 Mar; 53(10):849-56. PubMed ID: 19264241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting.
    Cuisset T; Frere C; Quilici J; Morange PE; Nait-Saidi L; Carvajal J; Lehmann A; Lambert M; Bonnet JL; Alessi MC
    J Am Coll Cardiol; 2006 Oct; 48(7):1339-45. PubMed ID: 17010792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting.
    Sibbing D; Morath T; Braun S; Stegherr J; Mehilli J; Vogt W; Schömig A; Kastrati A; von Beckerath N
    Thromb Haemost; 2010 Jan; 103(1):151-9. PubMed ID: 20062919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet function in clopidogrel-treated patients with acute coronary syndrome.
    Sibbing D; von Beckerath O; Schömig A; Kastrati A; von Beckerath N
    Blood Coagul Fibrinolysis; 2007 Jun; 18(4):335-9. PubMed ID: 17473574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy.
    Kastrati A; von Beckerath N; Joost A; Pogatsa-Murray G; Gorchakova O; Schömig A
    Circulation; 2004 Oct; 110(14):1916-9. PubMed ID: 15262828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
    Gurbel PA; Bliden KP; Hiatt BL; O'Connor CM
    Circulation; 2003 Jun; 107(23):2908-13. PubMed ID: 12796140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
    Serebruany VL; Malinin AI; Pokov AN; Hanley DF
    Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease.
    Migliorini A; Valenti R; Marcucci R; Parodi G; Giuliani G; Buonamici P; Cerisano G; Carrabba N; Gensini GF; Abbate R; Antoniucci D
    Circulation; 2009 Dec; 120(22):2214-21. PubMed ID: 19917884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The association of cigarette smoking with enhanced platelet inhibition by clopidogrel.
    Bliden KP; Dichiara J; Lawal L; Singla A; Antonino MJ; Baker BA; Bailey WL; Tantry US; Gurbel PA
    J Am Coll Cardiol; 2008 Aug; 52(7):531-3. PubMed ID: 18687246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical relevance of clopidogrel unresponsiveness during elective coronary stenting: experience with the point-of-care platelet function assay-100 C/ADP.
    Moerenhout CM; Claeys MJ; Haine S; Miljoen H; Bosmans JM; Vertessen F; Kluppels K; Van der Planken M; Vrints CJ
    Am Heart J; 2010 Mar; 159(3):434-8. PubMed ID: 20211306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.